

Amendments to the Specification:

Please replace the paragraph beginning at page 4, line 19, with the following:

--Figs. 6 and 7 show the sequence of the variable heavy chain, V_H , (SEQ ID NO: 1) (amino acid = SEQ ID NO:1; nucleotide = SEQ ID NO:9) and the variable light chain, V_L , (SEQ ID NO: 2) (amino acid = SEQ ID NO:2; nucleotide = SEQ ID NO:10) of the antibody 224F3.--

Please replace the paragraph beginning at page 20, line 7, with the following:

--Peptide linkers and their use are well-known in the art. See, e.g., Huston *et al.*, *Proc. Nat'l Acad. Sci. USA* 8:5879 (1988); Bird *et al.*, *Science* 242:4236 (1988); Glockshuber *et al.*, *Biochemistry* 29:1362 (1990); U.S. Patent No. 4,946,778, U.S. Patent No. 5,132,405 and Stemmer *et al.*, *Biotechniques* 14:256-265 (1993). In some instances, the peptide linker has no specific biological activity other than to join the regions or to preserve some minimum distance or other spatial relationship between the V_H and V_L . However, the constituent amino acids of the peptide linker can be selected to influence some property of the molecule such as the folding, net charge, or hydrophobicity. Single chain Fv (scFv) antibodies optionally include a peptide linker of no more than 50 amino acids, generally no more than 40 amino acids, preferably no more than 30 amino acids, and more preferably no more than 20 amino acids in length. In some embodiments, the peptide linker is a concatamer of the sequence Gly-Gly-Gly-Gly-Ser (SEQ ID NO:11), preferably 2, 3, 4, 5, or 6 such sequences. However, it is to be appreciated that some amino acid substitutions within the linker can be made. For example, a valine can be substituted for a glycine.--

Amdt. dated August 18, 2004

Reply to Notice to File Missing Parts of June 23, 2004

Please replace the paragraph beginning at page 43, line 11, with the following:

--Fluorescence assay for determination of FIXa activating potential of antibody fragments containing a hexa-histidine (SEQ ID NO:12) tag:

Materials:

Buffers:

- TBS: 25mM Tris; 150mM NaCl pH 7,5
- TBS / 2% BSA: 2g BSA/ 100ml TBS
- HNa: 25 mM HEPES, 175 mM NaCl, pH 7.35
- HNaBSA5: 5mg BSA/ml HNa-Puffer

Reagents:

- Penta - HIS antibody, BSA free (Qiagen)
- hFIXa β (ERL)
- hFX (ERL)
- Phospholipids:
- Fluorogenic substrate Pefluor FXa: CH₃SO₂-D-CHA-Gly-Arg-AMC.AcOH (Pentapharm LTD)
- PL/Ca⁺⁺/hFX/fluorogenic substrate - mix: Final concentration: 4.3mM CaCl₂; 9.4 μ M PL; 29.3nM hFX; 167 μ M fluorogenic substrate--

Please insert the accompanying paper copy of the Sequence Listing, page numbers 1 to 4, at the end of the application.